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We investigated peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands eﬀect on cell motility and the plasminogen
activator system using normal MCF-10A and malignant MCF-10CA1 cell lines. Ciglitazone reduced both wound-induced
migration and chemotaxis. However, the eﬀect was not reversed with pretreatment of cells with the PPAR-γ-speciﬁc antagonist
GW9662. Immunoblot analysis of conditioned media showed ciglitazone decreased plasminogen activator inhibitor-1 (PAI-1) in
both cell lines; this eﬀect was also unaltered by PPAR-γ antagonism. Alternatively, treatment with the ω-6 fatty acid arachidonic
acid (ArA), but not the ω-3 fatty acid docosahexanoic acid, increased both MCF-10A cell migration and cell surface uPA activity.
Pretreatment with a PPAR-γ antagonist reversed these eﬀects, suggesting that ArA mediates its eﬀect on cell motility and uPA
activitythroughPPAR-γ activation.Collectively,thedatasuggestPPAR-γ ligandshaveadiﬀerentialeﬀectonnormalandmalignant
cell migration and the plasminogen activation system, resulting from PPAR-γ-dependent and PPAR-γ-independent eﬀects.
1.Introduction
Af u n c t i o no fa n yt u m o rc e l lt h a ta l l o w sf o rp r o p a g a t i o n
of diseased cells is the ability for that tumor cell to invade
the surrounding tissue. One family of proteins involved in
this pathological process is the plasminogen activator (PA)
system [1, 2]. The PA system includes the urokinase-type
plasminogenactivator(uPA).uPAismostactivewhenbound
to its cell surface urokinase receptor, uPAR. In addition to
the role of the uPA/uPAR complex in the degradation of the
ECM, this complex plays a role in cell adhesion. uPAR is able
to engage cell surface integrins, allowing for attachment of
cellsexpressingtheuPA/uPARcomplextoothersurrounding
cells. Another key component is plasminogen activator
inhibitor-1 (PAI-1), the physiological inhibitor of uPA activ-
ity [1, 2]. PAI-1 binds uPA bound to the cell surface, forming
a PAI-1/uPA/uPAR complex that is then recognized by the
scavenger protein low-density lipoprotein receptor-related
protein (LRP), which internalizes the tertiary complex [3, 4].
Paradoxically, elevated levels of PAI-1 in breast cancer pa-
tients are associated with decreased patient survival [5].
Peroxisome proliferator-activated receptor-gamma
(PPAR-γ) is a transcription factor that is considered the
master regulator of adipogenesis [6, 7]. However, PPAR-γ
has been found in numerous cell lines, including endothelial
cells [8, 9], normal and malignant prostate epithelium
[10, 11], and normal and malignant breast epithelium [12].
PPAR-γ is a ligand-activated nuclear transcription factor
and the target of the thiazolidinedione (TZD) class of insulin
sensitizing drugs [6, 13]. Drugs in this family bind PPAR-γ,
resulting in the activation of the PPAR-γ/retinoid X receptor2 Journal of Oncology
(RXR) heterodimer. PPAR-γ then binds the PPAR response
element (PPRE) in the promoter of target genes, recruits
coactivators, and then the gene is transcribed. In addition
to TZD drugs, PPAR-γ has been shown to be activated by
the naturally occurring 15-deoxy-Δ12,14-prostaglandin J2
(15d-PGJ2) [14]. Although 15d-PGJ2 is a potent agonist for
PPAR-γ in vitro, there is data suggesting 15d-PGJ2 is not
found at a high enough concentration to act as an in vivo
ligand for PPAR-γ [15].
In addition to the TZD class of drugs and 15d-PGJ2,
PPAR-γ has also been shown to be activated by a number
of dietary fatty acids, speciﬁcally omega-3 (ω-3) and omega-
6( ω-6) fatty acids. A diet high in fat is associated with the
development ofanumber ofdiseases,including cardiovascu-
lar disease, type 2 diabetes mellitus, and a variety of cancers.
Dietaryfatintakehasbeenlinkedtoprostatecancerrisk[16],
colon cancer [17–19], and breast cancer [20]. Thoennes, et
al., showed diﬀerential transcriptional activity by PPAR-γ
following treatment of MCF-7 cells with ω-3 and ω-6 fatty
acids [21]. Treatment with ω-3 fatty acids inhibited levels
of PPAR-γ activation, while ω-6 fatty acids increase PPAR-γ
activity over control [21].
The goal of this study was to investigate the eﬀect of
PPAR-γ ligands on breast cancer cell motility and the plas-
minogen activator system. The TZD ciglitazone decreased
cell motility, independent of PPAR-γ. PAI-1 levels were lower
following ciglitazone treatment. The naturally occurring
PPARγ ligand 15d-PGJ2 also reduced wound-induced cell
migration. Interestingly, treatment with the ω-6 fatty acid
arachidonic acid (ArA) increased cell motility, while the ω-
3 fatty acid docosahexanoic acid (DhA) had no signiﬁcant
eﬀect. Our collective results suggest that the PPAR-γ ligand
ciglitazone decreases cell motility, in a PPAR-γ independent
manner, potentially though the down-regulation of PAI-1;
alternatively, the PPAR-γ ligand ArA promotes migration in
aP P A R - γ dependent manner that increases uPA.
2.MaterialsandMethods
2.1.CellCulture. MCF-10A and MCF-10CA1 cells(obtained
from Dr. F. Miller, Wayne State University, Detroit, Mich,
USA) were cultured as previously described [22, 23]. All
cell lines were cultured in DMEM:F12 (GIBCO, Invitrogen,
Carlsbad, Calif, USA) containing 5% horse serum (HyClone,
Logan, UT), 1% PSF (GIBCO, Invitrogen, Carlsbad, CA),
20mg/mL EGF (Invitrogen, Carlsbad, Calif, USA), 50ng/mL
hydrocortisone, 100ng/mL cholera toxin (CalBiochem, San
Diego, Calif, USA), and 10mg/mL insulin (GIBCO, Invitro-
gen, Carlsbad, Calif, USA). Cells were grown in a humidiﬁed
atmosphere of 5% CO2 at 37◦Ca sp r e v i o u s l yd e s c r i b e d
[1].
2.2. In Vitro Wound Healing Assay. Cells were plated at 1.0 ×
105 cells per well in a 12-well tissue culture treated plate as
detailed previously [24, 25]. At conﬂuence, cells were serum-
starved overnight. Cells were then scratched with the tip of
a sterile yellow pipet tip and serum-free media containing
various concentration of 15d-PGJ2 (Calbiochem, San Diego,
Calif, USA) or ciglitazone ranging to 10μM( C a y m a n
Chemical, Ann Arbor, Mich, USA) from ethanol stocks were
added to each well. Migration was monitored at 0, 6, and
12-hours using a Kodak MDS290 camera. Wound closure
was quantiﬁed by measuring distance as pixels between each
leading edge of the wound (10lines/wound) at each time
point using the measuring tool in Adobe Photoshop, with a
grid superimposed on image to guide measurements.
2.3. Modiﬁed-Boyden Chamber Assay. Following serum star-
vation, cells were treated with PPAR-γ ligands ranging to
10μMofciglitazone,ArA(ArA-sodiumsalt,Sigma,St.Louis,
Mo, USA), or DhA (DhA-sodium salt, Sigma, St. Louis,
Mo. USA) in serum-free media for 24 hours. Lower wells
of chamber contained DMEM:F12 plus 1mg/mL fatty-acid-
free bovine serum albumin (BSA, Sigma, St. Louis, Mo,
USA) with or without 5ng/mL EGF (Invitrogen, Carlsbad,
Calif, USA). Cells (1 × 105) were plated in upper wells in
DMEM:F12 containing 1mg/ml fatty-acid free BSA, above
a collagen IV coated, 10mm porated membrane. Chambers
were incubated at 37◦C for 6-hours in a humidiﬁed atmo-
sphere. Cells were ﬁxed and stained with Diﬀ-Quick (Dade-
Behring, Newark, DE). Cells that migrated to the under-
surface of the membrane were examined microscopically at
200x magniﬁcation. Each condition was done in triplicate,
with 4 ﬁelds counted per well [1]. In experiments with
GW9662, serum-starved cells were pretreated for 30 minutes
with GW9662 (5μM) (Calbiochem, San Diego, Calif, USA),
then ciglitazone or fatty acid treatment was added to cells for
24-hours. GW9662 is an irreversible PPAR-γ antagonist and
it was used at a concentration where it is selective for PPAR-γ
in cells [26, 27].
2.4. Cell Viability Assay. Cells were plated at 1.0 × 104 cells
per well in a 96-well tissue culture plate. Conﬂuent cells were
serum-starved 24 hours, then MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) reagent was added
to cells and incubated at 37◦C for 3-hours. Supernatant was
removed and cells were washed in PBS. DMSO was added
to cells and incubated at 37◦C for 30 minutes. Absorbance
was measured (Abs = 595nm) on a SpectraMax microplate
reader (Molecular Devices, Sunnyvale, Calif, USA).
2.5. Immunoblot Analysis. Conditioned media from treated
cellswascollectedandconcentratedwithcentrifugalconcen-
trators (Amicon Ultracel 30kD, Millipore, Billerica, Mass,
USA). Protein concentration was determined using BioRad
Protein DC assay (BioRad, Hercules, Calif, USA). Proteins
were separated by SDS-PAGE in 10% polyacrylamide and
electrotransferred to PVDF membrane. Phosphate buﬀered
saline/0.1% Tween-20 (PBS/Tween) buﬀer was used in all
steps of immunoblot analysis. Each step was preceded by
three 9-minute washes at room temperature. Nonspeciﬁc
binding was blocked by 5% nonfat dry milk for 30 minutes
at room temperature. Membrane was incubated at 4◦C
overnight with primary antibody diluted 1:1000 (unless
otherwise noted) in 1% nonfat dry milk. Membrane was
exposed for 1-hour at room temperature to horseradish
peroxidase conjugated secondary antibody diluted 1:5000 inJournal of Oncology 3
1% nonfat dry milk in PBS/Tween. Membrane was exposed
to luminal substrate for 1 minute, covered in plastic wrap
then exposed to X-ray ﬁlm. Primary antibodies were: rabbit
antihuman PAI-1 (1:2000 dilution) (Molecular innovations,
Novi, MI) and rabbit anti-human uPA (no. 389, American
Diagnostica, Stamford, Conn, USA) as described previously
[1].
2.6. Indirect Cell-Surface Associated UPA Activity Assay.
MCF-10A and MCF-10CA1 cells (1 × 105) were plated in
a 96-well plate [1]. Following 24-hour serum starvation,
c e l l sw e r ep r e t r e a t e dw i t hP P A R - γ antagonist GW9662 or
vehicle control for 30 minutes at 37◦C. Cells were then
treated with various concentrations (up to 10μM) of ci-
glitazone or arachidonic acid for 24 hours at 37◦C. After
treatment, cells were washed with PBS and plasminogen
was added to cells and incubated at room temperature.
The supernatant was removed and added to another 96-
well plate containing buﬀer amiloride to inhibit any residual
uPA activity. Chromogenic substrate is then added to the
well and hydrolyzed by plasmin generated by plasminogen
cleaved by uPA on the cell surface. Rate of chromogenic
substrate cleavage by plasmin was measured at 405nm for 90
minutes.
3. Results
3.1. Plasminogen Activator, PPAR-γ, and RXR in MCF-10A
and MCF-10CA1 Cells. As previously reported, MCF-10A
cells express less uPA and uPAR but more PAI-1 than MCF-
1CA1 breast cancer cells [1]. Both cell lines express PPAR-γ
and RXRs (data not included). Based on these ﬁndings, we
performed a study with some PPAR-γ ligands on uPA/PAI-
1-mediated cell migration processes comparing near normal
MCF-10A cells to oncogenic Ras-transformed metastatic
MCF-10CA1 cells.
3.2. PPAR-γ L i g a n d sD e c r e a s eI nV i t r oW o u n dC l o s u r e .
Ciglitazone decreased wound closure dose dependently
(Figure 1(a)), with 5μM ciglitazone reducing cell closure by
39% compared to no ciglitazone. 15d-PGJ2 also decreased
cell closure dose dependently, with 10μM 15d-PGJ2 reduced
cell closure by 50% compared to no 15d-PGJ2 (Figure 1(b)).
These results show that PPAR-γ ligands decrease wound
closure of MCF-10A cells, and they further support the
literaturethatPPAR-γ activationinhibitsmigrationofcancer
cells in vitro.
3.3. Ciglitazone Treatment Decreases Chemotaxis, Decreases
PAI-1 Expression, but Increases uPA Activity. Ciglitazone
decreased cell chemotaxis to EGF in a dose-dependent man-
ner (Figure 2). To determine if these eﬀects were medi-
ated by PPAR-γ, we pretreated the cells with the PPAR-γ
speciﬁc antagonist GW9662. Interestingly, blocking PPAR-
γ activation with GW9662 (5μM) pretreatment did not
reverse the eﬀect of ciglitazone (5μM) in either cell line.
Control experiments with 5μM GW9662 showed neither
detrimental eﬀect on cell viability nor changes in cell mo-
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Figure 1: PPAR-γ ligands decrease wound closure in MCF-10A
cells. Ciglitazone (a) and 15d-PGJ2 (b) were added to cells, and
wound-induced closure measured as detailed under Section 2.D a t a
shown are the 12-hour time point + SD (n = 3)
∗∗P < 0.01.
tility. The data suggest ciglitazone is working in a PPAR-γ
independent manner to reduce cell migration. The eﬀect of
ciglitazone on cell viability was then determined by MTT
assay. Treatment of MCF-10A and MCF-10CA1 cells with
5μM ciglitazone partially reduced cell viability (Abs 595nm
of cells with no and 5μM ciglitazone was 0.331 ± .014
and 0.292 ± .003 for MCF-10A cells and 0.304 ± .006 and
0.279 ± .002 for MCF-10CA1 cells, resp.). There was a
substantial loss of cell viability at 10μM ciglitazone for both
celllines;thus,allfurtherexperimentsused5μMciglitazone.
In additional control experiments, there was no loss of cell
viability with the PPAR-γ ligands 15d-PGJ2 or ArA when
tested up to 10μM (data not included). These results imply
that the eﬀect of ciglitazone in MCF-10A and MCF-10CA1
cell motility is not due to a substantial reduction in cell
viability.
In both MCF-10A and MCF-10CA1 cell lines, ciglitazone
treatment resulted in decreased PAI-1 protein expression
(Figure 3). To determine if this decrease in PAI-1 expression
was mediated by PPAR-γ, we pretreated with GW9662 pri-
or to ciglitazone treatment. We did not see a reversal4 Journal of Oncology
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Figure 2: Ciglitazone decreases chemotaxis in MCF-10A (a) and
MCF-10CA1 cells (b). Chemotaxis to either BSA (1mg/mL fatty-
acid free BSA) or to EGF (5ng/mL EGF in 1mg/mL fatty acid free
BSA) was performed as detailed under Section 2. Each condition
was done in triplicate. Values represent total number of cells per
well + SD (n = 3)
∗P < 0.05.
of ciglitazone-mediated reduction in PAI-1 expression
(Figure 3) suggesting ciglitazone is aﬀecting PAI-1 levels
independently of PPAR-γ.
In MCF-10A cells, ciglitazone treatment alone or in con-
junction with GW9662 pretreatment increases uPA activity
on the cells surface (Figure 4(a)). Ciglitazone treatment in
MCF-10CA1 cells did not signiﬁcantly alter uPA activity
although it seems GW9662 treatment in these cells results in
more plasmin generation (Figure 4(b)).
+
+ +
+ +
+ +
+ +
+ +
+ +
+ +
+
DMSO
Ethanol
5µM GW9662
MCF-10A MCF-10CA1
IB: PAI-1
5µM ciglitazone
Figure 3: Ciglitazone decreases PAI-1 expression in MCF-10A and
MCF-10CA1 cells and is not reversed by PPAR-γ antagonist pre-
treatment. Conditioned media from cells treated with ciglitazone
(0–5μM), in the absence and presence of 5μM GW9662, was
concentrated and 10μg total protein was separated by SDS-PAGE
on a 10% polyacrylamide gel. Proteins were then transferred to
PVDF membrane and probed for PAI-1 (rabbit antihuman PAI-1
antiserum) as detailed under Section 2.
3.4. Arachidonic Acid Increases Both MCF-10A Cell Motil-
ity and uPA Activity. With 10 μM ArA, we see a signif-
icant increase in cell motility compared to control cells
(Figure 5(a)). When we pretreated the MCF-10A cells with
the PPAR-γ antagonist GW9662, we see a reduction in cell
motility (Figure 5(a)). ArA treatment increases uPA activity
on the cell surface though GW9662 did not seem to fully
reduce uPA activity (Figure 5(b)). Additionally, treatment
with the ω-3 fatty acid DhA, up to 10μM, had no eﬀect on
either cell motility or cell viability (data not shown). These
results suggest ArA is able to activate PPAR-γ, resulting in
increased cell motility and uPA activity.
4. Discussion
PAI-1 and uPA protein expression have been used as strong
independent prognostic indicators for breast cancer [5, 28–
30]. In addition to cancer, PAI-1 overexpression is linked to
a variety of disease states. Morbidly obese individuals have
elevated circulating PAI-1 levels, likely due to an increase
in PAI-1 expression from adipose tissue [31]. In rats with
streptozocin-induced diabetes, PAI-1 levels are increased 60–
80% over control [32]. In humans, elevated PAI-1 levels have
been reported in patients with T2DM [33] and is related
to cardiovascular dysfunction [33, 34]. While the literature
on PPAR-γ activation and PAI-1 alterations is conﬂicting,
it has been shown in a number of cell types and in vivo
that PPAR-γ does modulate PAI-1 expression [34–37]. We
treated cells with ciglitazone, 15d-PGJ2, and ArA acid to
investigate eﬀects of PPAR-γ activation on migration and
PAI-1 expression following treatment. Based on previous
literature, we expected to see diﬀerential eﬀects of PPAR-γ
activation, speciﬁcally with ArA treatment [21].
In vitro, treatment of tumor cells with TZDs results
in a number of antitumor eﬀects. In prostate cancer cells,
PPAR-γ ligands reduced proliferation, induced terminal
diﬀerentiation, and downregulated E-cadherin and c-myc
expression [38]. Pioglitazone, in combination with valproicJournal of Oncology 5
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Figure 4: Ciglitazone treatment increases uPA activity in MCF-
10A cells (a) but not in MCF-10CA1 cells (b). Following 24-hour
treatment with ciglitazone (0–5μM), in the absence and presence
of 5μM GW9662, media was removed from cells, washed in 1x
PBS and plasminogen was then added, after 30-minutes at room
temperature, cell supernatant was transferred to wells containing
plasmin chromogenic substrate (S-2251, Chromogenix). Kinetics
were read at 405nm for 1.5-hours at 37◦C. Values represent average
Vmax at Ab 405nm, normalized to no treatment control, each
condition done in triplicate (n = 3)
∗P < 0.05.
acid, upregulates E-cadherin and reduced invasion and
migration in prostate cancer cells [39]. We found that
treatment with either ciglitazone or 15d-PGJ2 resulted in
a signiﬁcant decrease in wound closure of MCF-10A cells.
Ciglitazone treatment decreased chemotaxis toward EGF in
both MCF-10A and MCF-10CA1 cells. GW9662 is a speciﬁc
PPAR-γ antagonist, which binds PPAR-γ and blocks ligand
binding and subsequent activation of the receptor [40].
Surprisingly, pretreatment with GW9662 did not reverse
N
o
t
r
e
a
t
m
e
n
t
5
µ
M
G
W
9
6
6
2
1
0
µ
M
A
r
A
A
r
A
/
G
W
0
1
2
3
∗∗
F
o
l
d
c
h
a
n
g
e
(
o
v
e
r
n
o
t
r
e
a
t
m
e
n
t
)
(a)
N
o
t
r
e
a
t
m
e
n
t
5
µ
M
G
W
9
6
6
2
1
0
µ
M
A
r
A
A
r
A
/
G
W
0
1
2
3
4 ∗
A
v
g
.
V
m
a
x
(
n
o
r
m
a
l
i
z
e
d
t
o
n
o
t
r
e
a
t
m
e
n
t
)
(b)
Figure 5: Arachidonic acid treatment increases MCF-10A cell
motility(a)anduPAactivity(b).MCF-10Acellsweretreatedfor24-
hours in serum-free media containing 10μM ArA or vehicle control
(absolute ethanol in DMEM:F12 containing 1mg/mL fatty acid-
free BSA) following a 30min pretreatment with GW9662 (5μM)
or vehicle (DMSO) as detailed under Section 2. Values represent
average number of cells chemotaxing to EGF/well + SD. n =
3
∗∗P < 0.01. Separately, after receiving the same treatment as
above,cellswerewashedinPBS,thenincubatedinbuﬀercontaining
plasminogen. Supernatant from cells was transferred to a new
well containing buﬀer, amiloride and plasmin substrate. Values
represent average Vmax (Abs 405nm) + SD (n = 3)
∗P < 0.05.
the eﬀects of ciglitazone, which suggests that ciglitazone
mediates this reduction in migration through a PPAR-γ-
independent mechanism. Emery et al. showed rosiglitazone
and pioglitazone inhibited proliferation of pituitary tumors;
however, PPAR-γ antagonists did not reverse these eﬀects,
suggesting the antiproliferative eﬀect was independent of
PPAR-γ activation[41].Anotherstudyfoundciglitazoneand
15d-PGJ2 induced apoptosis in normal and malignant B6 Journal of Oncology
cell, independent of PPAR-γ [42]. Finally, ciglitazone and
15d-PGJ2 have been shown to activate p38 MAPK signaling,
which were reported to be independent of PPAR-γ activation
[43, 44].
Interestingly, ArA treatment of MCF-10A cells enhanced
cell migration. These eﬀects were reversed in cells pretreated
with GW9662, suggesting ArA is acting in a PPAR-γ-
dependent manner. Since ω-3 and ω-6 fatty acids have
been shown to have diﬀerential eﬀects on PPAR-γ activation
[21], we also investigated if ω-3 fatty acids had an eﬀect
on cell migration in our system. We saw no change in
migration in MCF-10A cells treated with DhA, which
agrees with past studies that ω-6, but not ω-3, fatty acids
promote cell motility [45]. GW9662 pretreatment did not
fully reverse ArA-induced uPA activity; one possibility for
this is ArA also signals through PI3K [46] to upregulate
uPA expression [47]. It is also possible ArA is engaging
PPAR-γ intracellularly, resulting in increased cell migration,
while independently initiating the PI3K signaling cascade
and then upregulating uPA activity. One limitation of our
study was the exclusive use of GW9662 for its irreversible
PPAR-γ antagonist eﬀect [26, 27]. Future studies with
MCF-10A and MCF-10CA1 cells would beneﬁt from either
silencing PPAR-γ expression or expressing a dominant
negative PPAR-γ to investigate any possible diﬀerences in
cell motility or proliferation following treatment with cigli-
tazone or other PPAR-γ agonists. Another limitation to our
study was the absence of reporter studies for PPAR-γ gene
regulation.
TZDs may be useful adjuvant therapies in cancer treat-
ment. One clinical trial in phasetwo investigated the eﬀect
of pioglitazone in conjunction with a COX-2 inhibitor in
glioma patients and saw moderate results in patients with
high-gradeglioma,suggestingpioglitazonetreatmentmaybe
beneﬁcialtoasubsetofpatients[48].Aphase-Itrialofanon-
TZD PPAR-γ agonist LY29311 studied maximum tolerated
dose in a combination regimen in patients with advanced
solid tumors and determined there was no limiting toxicity
andnodiseaseprogression[49].Todate,theseadvanceshave
not been realized with PPAR-γ agonists in contrast to their
preventative beneﬁts in diabetic patients.
5. Conclusions
This study shows ciglitazone treatment reduces both normal
and malignant epithelial cell migration in vitro, indepen-
dently of PPAR-γ activation. Additionally, we found ciglita-
zone treatment reduces PAI-1 protein levels, and this eﬀect
was not reversed by antagonism of PPAR-γ. We hypothesize
that the antimigratory eﬀects of ciglitazone are mediated by
the alteration of the PA system in these cells. We know PAI-
1 inhibits apoptosis, can promote cell motility, and plays
a role in intracellular signaling [1, 2]. Given the role of
PAI-1 in these tumor processes, the in vivo data showing
FDA-approved TZDs decrease PAI-1 in diabetic patients,
and our results and those of others, one could draw the
conclusion that TZD therapies may eventually prove to be
a valid adjuvant therapy for some breast cancer patients.
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